Clinical Trial Update: High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating high-dose irinotecan (CPT-11) in patients with recurrent unresectable malignant glioma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Irinotecan (Irinotecan)

Snippet

Sponsor: Kentuckiana Cancer Institute | Conditions: Malignant Glioma | Phase 1, Phase 2 | Status: COMPLETED